Question thread · 2 questions
Whether the recent National Institute of Clinical Excellence ruling on Aricept will mean that Al'heimer's patients across Scotland will have access to the drug.
Started with S1W-12788 on 24 Jan 2001; latest 9 May 2001. Each later question says it follows up an earlier answer.
Follow-ups
1
Span
105 days
Answered
2 of 2
Asked by
2
The thread, in order
Each answer’s opening lines; open a question for the full text-
To ask the Scottish Executive whether the recent National Institute of Clinical Excellence ruling on Aricept will mean that Al'heimer's patients across Scotland will have access to the drug.
Susan Deacon, 7 Feb 2001: The Health Technology Board for Scotland is currently working on a process to comment on all Final Appraisals from the National Institute for Clinical Excellence (NICE). The NICE Appraisal on donepezil (Aricept), rivastigmine (Exelon) and galantamine (Reminyl) will be the first to go through this process in the spring… -
When Aricept will be made available throughout the National Health Service in Scotland.
Susan Deacon, 22 May 2001: Donepezil (Aricept) has been licensed since 1997 for the treatment of mild to moderate dementia in Alzheimer's disease. The use of this treatment depends on the clinical judgement of the clinician concerned, taking into account advice and evidence about its use. This will include the Health Technology Board for Scotla…
How this thread is put together
- Follow-up
- A question whose text says it is “further to the answer to question …” (or reply, response, or asks for a “substantive answer” to an earlier question). The question it names is its parent.
- Several citations
- When a question cites more than one earlier question, the most recent one we hold is used as the parent; the others are listed as “also cites”.
- Thread
- Follow parents back to the first question; every question that leads back to it is in this thread. Branches are shown in date order.